KRAS mutation: from undruggable to druggable in cancer
Abstract Cancer is the leading cause of death worldwide, and its treatment and outcomes have been dramatically revolutionised by targeted therapies. As the most frequently mutated oncogene, Kirsten rat sarcoma viral oncogene homologue (KRAS) has attracted substantial attention. The understanding of...
Enregistré dans:
Auteurs principaux: | Lamei Huang, Zhixing Guo, Fang Wang, Liwu Fu |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Nature Publishing Group
2021
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/376e4538053644209dbda716fe11e25a |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Targeting the undruggable: an interview with Leila Akkari on fighting cancer by rewiring cells
Publié: (2021) -
Target inhibition networks: predicting selective combinations of druggable targets to block cancer survival pathways.
par: Jing Tang, et autres
Publié: (2013) -
Identification of a targetable KRAS-mutant epithelial population in non-small cell lung cancer
par: Giorgia Maroni, et autres
Publié: (2021) -
Mutational burden and chromosomal aneuploidy synergistically predict survival from radiotherapy in non-small cell lung cancer
par: Qingzhu Jia, et autres
Publié: (2021) -
Using CRISPR to understand how cancer mutations happen
par: Eve H. Rogers
Publié: (2021)